DNA methylation landscape reveals GNAS as a decitabine-responsive marker in patients with acute myeloid leukemia

Background: The demethylation agent decitabine (DAC) is a pivotal non-intensive alternative treatment for acute myeloid leukemia (AML). However, patient responses to DAC are highly variable, and predictive biomarkers are warranted. Herein, the DNA methylation landscape of patients treated with a DAC...

Full description

Bibliographic Details
Main Authors: Shujiao He, Yan Li, Lei Wang, Yisheng Li, Lu Xu, Diya Cai, Jingfeng Zhou, Li Yu
Format: Article
Language:English
Published: Elsevier 2024-03-01
Series:Neoplasia: An International Journal for Oncology Research
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558624000022